How to Sell to Biotech Startups: A 2026 BD Playbook
- Imen Jelassi
- 6 hours ago
- 9 min read
Key Takeaways
More money, far fewer buyers. Private bio/pharma funding in H1 2026 reached about $20.3 billion, the highest three-year total, but across only 366 funding events, down 32% from 535 a year earlier and 46% from 684 in H1 2024.
Your target list is mostly clinical-stage, not discovery-stage. Of the 68 venture-backed biotechs that raised more than $9.1 billion in H1 2026, roughly two-thirds (42 rounds) went to companies that already had a drug candidate in human testing.
The money is concentrated in megarounds. About 76% of first-half venture funding came in rounds of $100 million or more, so a small number of accounts carry most of the addressable spend.
Small companies outsource the most. Small and mid-sized biotechs outsource an estimated 65% to 70% of their activities, against roughly 40% to 45% for large pharma, which means a newly funded 15-person biotech is a buyer from day one.
The window is 30 to 90 days. Vendor decisions cluster in the first quarter after a raise, before the round is fully staffed. Arriving in month six means arriving after the shortlist was set.
Most business development advice about emerging biotech was written for a market that no longer exists. It assumes a wide funnel: hundreds of newly funded companies each year, most of them small, most of them discovery-stage, most reachable through volume outreach to a generic info@ address. Build a big list, send a lot of email, wait for the ones with money to surface.
That approach is now actively counterproductive, and the 2026 data explains why. The funding rebound is real, but it arrived in a shape that punishes volume and rewards precision. Fewer companies are getting funded. The ones that do are getting much more. And they are further along the clinical path than the biotechs your playbook was built around.
The practical answer to how to sell to biotech startups in 2026 is not a better cold email. It is a shorter list, a faster trigger, and a much clearer idea of who inside a 15-person company actually signs.
The rebound is real, and it is narrower than the headlines suggest
Two datasets tell the same story from different angles.
Private bio/pharma funding tracked by BiopharmIQ reached approximately $20.3 billion in H1 2026, slightly above both H1 2025 ($19.7 billion) and H1 2024 ($19.2 billion). On dollars alone, that is a recovery. On company count, it is a contraction.
Metric | H1 2024 | H1 2025 | H1 2026 |
Total private funding | ~$19.2B | ~$19.7B | ~$20.3B |
Total funding events | 684 | 535 | 366 |
Early-stage funding | ~$5.94B | ~$5.40B | ~$3.97B |
Early-stage events | 229 | 198 | 137 |
Roughly the same amount of capital is now reaching about half as many companies as two years ago. Early-stage funding fell hardest, down to about $3.97 billion across 137 events from $5.94 billion across 229 events in H1 2024.
BioPharma Dive's venture tracker points the same direction. At least 68 biotech companies raised more than $9.1 billion between January and June 2026, the highest first-half sum since the start of 2022 among the firms it tracks. About 76% of that total came in megarounds of $100 million or more. Two-thirds of the rounds, 42 of them, went to companies that already had a drug prospect in human testing.
That last figure is the one to write down. It means the median newly funded biotech in 2026 is not a founder with a platform and a hypothesis. It is a company with a clinical asset, real timelines, and immediate need for services it cannot build in-house.
Public markets reinforced the pattern. The XBI biotech ETF rose about 30.2% across H1 2026, 15 biotech IPOs priced in the first half (up 114% from seven a year earlier, the strongest first half since 2021), and the 13 companies in BioPharma Dive's IPO tracker raised a combined $4.5 billion at a median of almost $302 million each.
Why fewer, richer buyers change how to sell to biotech startups
If your target universe halves while the average budget doubles, every assumption behind volume outreach breaks.
A 500-account list built from a funding database is now mostly noise, because the companies that did not raise are not buying. Meanwhile the 40 or 50 accounts that did raise are being contacted by every CRO, CDMO, consultant, and software vendor in the sector at the same time, in the same week, with the same congratulations-on-your-Series-A opening line.
The competitive dynamic shifts from reach to differentiation under crowding. You are not trying to be seen. You are trying to be the third or fourth message that says something the first two did not.
That argues for a much smaller list researched much more deeply, which is the opposite of what most BD teams do when a market tightens. The instinct under pressure is to widen the funnel. In a concentrated market, widening the funnel dilutes exactly the research capacity that would have won the accounts worth winning. We covered the structural version of this trade-off in our guide to pharmaceutical lead generation, and the 2026 funding data makes the case sharper than it was even a year ago.
The three triggers worth building a list around
Trigger-based prospecting works in this market because the triggers are public, dated, and tightly correlated with buying. Three matter.
Trigger | Typical decision window | What the company is buying | What to lead with |
Series A or B close | 30 to 90 days post-announcement | First external CRO/CDMO partners, IND-enabling work, tox, CMC | Speed to first study, named team, realistic timeline |
Crossover or pre-IPO round | 60 to 120 days | Scale-up, registrational trial capacity, commercial-readiness CMC | Capacity guarantees, inspection history, tech transfer record |
IPO pricing | 30 to 60 days | Expansion of existing programs, second indication, manufacturing scale | Ability to absorb increased scope on an existing relationship |
The Series A window is the one most BD teams misjudge. The instinct is to wait until the company has hired a head of operations or a VP of technical operations, on the theory that there is then someone to talk to. By the time that hire is made, usually four to six months after the raise, the first vendor decisions have already been taken by the founders, often based on relationships that predate the round.
Arriving in month six is arriving after the shortlist. Arriving in week three, with something specific, is arriving while the shortlist is being written.
Who actually buys inside a 15-person biotech
At a newly funded biotech of 10 to 25 people, the org chart you are used to selling into does not exist. There is no procurement function, no vendor management office, and frequently no full-time operations lead.
Decisions concentrate in three places.
The CEO or founder-CSO. At Series A stage this person personally selects the first CRO and CDMO partners, usually from their own network, and usually fast. They are scientifically deep, commercially impatient, and allergic to capability decks. They respond to specificity about their molecule, their modality, and their timeline.
The head of preclinical or technical operations, if one exists. Often the first senior operational hire after the raise. This person inherits vendor relationships they did not choose and is the most likely internal champion for a switch at the second program.
The board member or venture partner. Frequently the most underrated influencer. VCs place preferred vendors across their portfolio companies, and a warm introduction through an investor bypasses the crowded inbox entirely. For a boutique service provider, one strong relationship with a mid-sized life sciences fund can be worth more than a year of outbound.
The practical implication for outreach targeting is that you are writing to a scientist-executive, not a procurement professional, and increasingly you should be routing through investors rather than around them. Our guide to LinkedIn prospecting in pharma and biotech covers the mechanics of mapping these three roles before the first message goes out.
What newly funded biotechs actually buy
The outsourcing intensity of small companies is the structural reason this segment is worth the effort. Small and mid-sized biopharma companies outsource an estimated 65% to 70% of their activities, compared with roughly 40% to 45% at large pharma. A 15-person biotech with $80 million in the bank is not building a tox facility or a fill/finish line. It is buying almost everything.
Sequencing matters more than the list. In the first year post-Series A, a clinical-stage company typically commits to IND-enabling toxicology, analytical development and CMC, drug substance and drug product manufacturing, regulatory strategy support, and a clinical operations partner for the first-in-human study. Those decisions are made roughly in that order, which means the window for each service is different, and a generic capabilities pitch lands at the wrong moment for most of them.
Modality also concentrates the opportunity. Immune and cancer-focused drug developers accounted for more than 40% of H1 2026 funding rounds. Biologics and small molecules each attracted more than $2 billion, while cell and gene therapy developers remained in a multi-year slump at roughly $2 billion for the year. If your capability set is weighted toward cell and gene, the 2026 funding data says your addressable list is materially thinner than it looks, and that is worth knowing before you build the quarter's plan around it.
The outreach itself: what works after a raise
Three things separate the messages that get replies from the ones that do not.
Reference the asset, not the round. Every competitor opens with congratulations on the financing. Opening with a specific, accurate observation about the molecule, the modality, or the stated development timeline signals that someone read the pipeline page rather than a funding alert. It also happens to be the only opening a founder-CSO finds interesting.
Lead with a constraint you can remove. Newly funded biotechs are time-constrained, not budget-constrained, which is a reversal from the 2023 to 2024 market. Slot availability, a named project manager, a realistic date for first study start, these are worth more than a price concession. Discounting into this segment reads as capacity you cannot fill.
Make the first ask small. A 20-minute technical conversation with a named scientist converts far better than a request for a capabilities presentation. The founder is deciding whether your team is credible, and that decision is made by talking to a scientist, not by watching slides.
For the structural elements of the message itself, subject lines, length, sequencing, and follow-up cadence, our life sciences email outreach templates cover the patterns that hold up in this segment.
What not to do
Do not buy a large list. In a market of 366 funding events per half, a list of 2,000 emerging biotechs is mostly companies that did not raise and cannot buy.
Do not wait for the operations hire. The first vendor decisions precede it.
Do not pitch discovery services to a clinical-stage company. Two-thirds of funded rounds in H1 2026 went to companies already in human testing. Leading with discovery capability tells a clinical-stage CSO that you did not check.
Do not treat the IPO cohort as new logos. Companies that priced an IPO in 2026 mostly have incumbent service relationships from their private years. The opportunity there is scope expansion through the incumbent's gaps, not displacement.
Do not ignore the investor layer. In a concentrated market, portfolio-level relationships compound in a way that individual outbound does not.
The underlying discipline is the same one that governs any tightening market: fewer targets, deeper preparation, faster response to public triggers. That is a pipeline design question rather than an outreach volume question, and we set out the full framework in our guide to pipeline optimization for life sciences.
Frequently asked questions
Is 2026 actually a good year to target newly funded biotechs?
Yes, but for different reasons than in 2021. Total capital is up (about $20.3 billion in private bio/pharma funding in H1 2026, the highest three-year total), yet the number of funding events fell to 366 from 535 a year earlier. The addressable list is smaller and better funded. That favours service providers who can research deeply and respond quickly, and penalises those competing on outreach volume.
How soon after a funding round should I make contact?
Within 30 days for a Series A or B, and no later than 90. First vendor decisions at early-stage companies are typically taken by the founders within the first quarter after close, often before an operations lead is hired. Waiting for that hire, which usually lands four to six months post-raise, means arriving after the shortlist has been set.
Who is the right contact at a 15-person biotech?
Usually the CEO or founder-CSO, who personally selects the first CRO and CDMO partners at this stage. The head of preclinical or technical operations, once hired, becomes the champion for the second program. The most underused route is the investor: venture partners place preferred vendors across portfolio companies, and an introduction through the board bypasses a very crowded inbox.
What services do newly funded biotechs buy first?
For a clinical-stage company post-Series A, the typical sequence is IND-enabling toxicology, analytical development and CMC, drug substance and drug product manufacturing, regulatory strategy, and then a clinical operations partner for first-in-human work. Because each decision has its own window, a generic capabilities pitch arrives at the wrong moment for most of them. Small and mid-sized biotechs outsource an estimated 65% to 70% of their activities, so the total opportunity per account is large.
Should I focus on cell and gene therapy startups?
Only if that is genuinely your core capability. Cell and gene therapy developers remained in a multi-year funding slump through H1 2026, on pace for roughly $2 billion for the year, while immune and cancer-focused developers took more than 40% of funding rounds and biologics and small molecule companies each attracted more than $2 billion. The addressable list in cell and gene is materially thinner than the sector's visibility suggests.
Sources
Double Helix Law, "H1 2026 Private Bio/Pharma Funding: Environment Remained Challenging," July 15, 2026 (data source: BiopharmIQ): doublehelixlaw.com
BioPharma Dive, "Biotech startup funding gap widens despite rebound in VC investment," July 13, 2026: biopharmadive.com
Double Helix Law, "Bio/pharma IPO Market Selectively Opens in H1 2026," July 16, 2026: doublehelixlaw.com
BioPharma Dive, biotech IPO performance tracker: biopharmadive.com
BioPharma Dive, "Cancer, immune drug developers dominate venture funding," 2026: biopharmadive.com
BioPharmaTrend, "The CRO Industry in Flux: Trends in Pharma R&D Outsourcing": biopharmatrend.com
McKinsey & Company, "CROs and biotech companies: Fine-tuning the partnership": mckinsey.com
Comments